People · Operator
Named in public records as an officer, director or promoter · active 2019–2023 · Other Technology, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| 908 Devices Inc. | — | Other Technology | Series B | $68.2M | $533.0M | 2019 |
| NanoCellect Biomedical, Inc. | — | Biotechnology | Series B | $58.6M | $322.9M | 2021 |
Nicolas Barthelemy at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nicolas Barthelemy on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| PAUL CONLEY | 1 | 17 |
| Christopher Brown | 1 | 16 |
| Keith Crandell | 1 | 11 |
| Jack Ball | 1 | 10 |
| Mark Spoto | 1 | 8 |
| Kenneth Hood | 1 | 3 |
| Nicholas Barthelemy | 1 | 3 |
| Sharon Kedar | 1 | 3 |
| Jeremy Baker | 1 | 2 |
| Kevin Hrusovsky | 1 | 2 |
| J. Michael Ramsey | 1 | 2 |
| Jose Morachis | 1 | 1 |
| William Alaynick | 1 | 1 |
| Nate Heintzman | 1 | 1 |
| Mark Michael Spoto | 1 | 1 |
| Joseph Griffith | 1 | 1 |
| Chris Neary | 1 | 1 |
| Alexis Ji | 1 | 1 |
| Kevin Crandell | 1 | 1 |
| Kevin Knopp | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.